Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript

Cencora, Inc. (NYSE: COR) Q1 2026 Earnings Call dated Feb. 04, 2026

Corporate Participants:

Bennett Murphy — Senior Vice President of Investor Relations

Robert Mauch — President and CEO

James Cleary — Executive Vice President & CFO

Analysts:

Glen Santangelo — Analyst

Elizabeth Anderson — Analyst

Lisa Gill — Analyst

Michael Cherny — Analyst

Erin Wilson Wright — Analyst

Stephen Baxter — Analyst

Eric Percher — Analyst

Allen Lutz — Analyst

Charles Rhyee — Analyst

George Hill — Analyst

Steven Valiquette — Analyst

Kevin Caliendo — Analyst

Daniel Grosslight — Analyst

Presentation:

operator

Hello everyone and thank you for joining the Sencora fiscal 2026 first quarter results call. My name is Lucy and I’ll be coordinating your call today. During the presentation, you can register a question by pressing STAR followed by one on your telephone keypad. If you change your mind, please press STAR followed by two. It is now my pleasure to hand over to your host, Bennett Murphy, Senior Vice President of Investor Relations and Enterprise Productivity. To begin, please go ahead.

Bennett Murphy — Senior Vice President of Investor Relations

Good morning, Good afternoon. Thank you all for joining us for this conference call to discuss Sencora’s fiscal 2026 first quarter results. I am Bennett Murphy, Senior Vice President, Investor Relations and Enterprise Productivity. Joining me today are Bob Machine, President, CEO, and Jim Cleary, Executive Vice President and cfo. On today’s call we will be discussing non GAAP financial measures. Reconciliations of these measures to GAAP are provided in today’s press release which is available on our website@investor.syncor.com We’ve also posted a slide presentation to accompany today’s press release on our investor website. During this conference call we will discuss forward looking statements about our business and financial expectations on adjusted non GAAP basis including without limited to etf, operating income and income taxes.

Forward looking statements are based on management’s current expectations, are subject to uncertainty and change. For a discussion of key risks and assumptions, we refer to today’s press Release and our SEC filings, including our most recent 10K. STCOR assumes no obligation to update any forward looking statements and this call cannot be rebroadcast without the permission of the company. You have an opportunity to ask questions after today’s remarks by management. We expect you to limit your questions to one per participant in order for us to get to as many as possible within the hour. With that, I’ll turn the call over to Bob.

Robert Mauch — President and CEO

Thank you Bennett. Hi everyone and thank you for joining Syncor’s fiscal 2026 first quarter earnings call. I’ll begin by thanking our team members who drive our strong performance while advancing our purpose. This morning we were pleased to announce that we’ve completed our acquisition of the majority of the remaining equity interests in One Oncology. And I welcome CEO Dr. Jeff Patton and the entire One Oncology team to Sencora. Your commitment to an expertise in supporting community oncology practices is a cornerstone of the SENCORA Strategy. In the first quarter of fiscal 2026 we delivered adjusted operating income growth of 12% and adjusted diluted EPS growth of 9% driven by our market leading capabilities to reflect our performance and the contribution from our recently completed acquisition of One Oncology.

We are raising our fiscal 2026 guidance to reflect year over year adjusted operating income growth of 11.5 to 13.5%. Our results were driven by continued strength in our US Healthcare Solutions business as we executed our pharmaceutical centric strategy and worked to advance commercial solutions. Our dedication to understanding customer needs and delivering tailored services creates long standing strategic relationships fueling our growth. We are furthering the customer experience and our operational excellence, leveraging technology and advanced analytics. Our solutions differentiate us in the market and allow us to capitalize on strong specialty pharmaceutical utilization trends. We have three growth priorities core to our strategy first, strengthening our leadership and specialty second, leading with market leaders and lastly, enhancing patient access to pharmaceuticals.

On today’s call, I’ll focus on how our MSO expansion is advancing each growth priority. I’ll begin with how our MSO footprint strengthens our leadership and specialty Our investments in pharmaceutical centric MSOs represent a natural extension of our long standing leadership in specialty pharmaceuticals. Complementing our existing specialty distribution and GPO services, our MSOs provide practices with critical back office and administrative support while strengthening our relationship with pharmaceutical companies. We expect to drive significant value for physicians across One Oncology and Retina Consultants of America by creating an MSO platform that leverages the capabilities of these market leaders.

We’ll unlock new opportunities to enhance our solutions for both providers and biopharma by leveraging our platform strengths and scale in areas like clinical research, revenue cycle management and data driven clinical insights to support physicians and advanced care. Focusing on our growth priority of leading with market leaders, our MSOs demonstrate the value of our commitment to support healthcare leaders at the forefront of innovation. While much focus today will be appropriately on completing the acquisition of One Oncology, in January, we celebrated the one year anniversary of RCA joining Syncora. Over the past year, we’ve been very pleased with the addition of RCA both in terms of their performance and leadership in driving pharmaceutical innovation.

RCA has clearly differentiated itself through its clinical trial and research capabilities, contributing to more than one third of all retina clinical trial research conducted in the United States and we see significant potential extending this offering across our MSO platform. In addition to expanding research capabilities, RCA physicians continue to enhance the patient care journey by adopting advanced technologies in their practices that have a meaningful impact on patient experience. Since completing the acquisition, we’ve supported the deployment of hundreds of advanced imaging devices across RCA practices that enable more precise, non invasive assessment of patients clinical conditions and finally, our MSO expansion is supporting our growth priority of Enhancing Patient Access to Pharmaceuticals as specialty pharmaceutical innovation continues to accelerate, physicians are navigating more advanced treatment options while facing increased operational complexity.

Our MSOs help address these challenges by providing a robust portfolio of services that support physicians in delivering the most modern, high quality care. Both RCA and one Oncology physicians are active contributors at leading retina and oncology conferences presenting research across a wide range of disease states. Recently, one Oncology partner practices presented dozens of abstracts covering emerging treatments including cellular therapies, subcutaneous bispecific antibodies and CAR T. These activities highlight the important role one Oncology physicians play in advancing cancer care and expanding access to complex treatments for patients in local communities. Another recent example of our MSO physicians leadership advancing clinical practice is RCA’s research chair, Dr.

Charles Wyckoff and team performing the world’s first procedure of a new FDA approved cell based gene therapy for Mactel type 2, a degenerative retina disease that previously had limited treatment options. We’ve also seen the real world impact of this leadership in the retina biosimilar market. RCA physicians were highly involved in supporting research for a key biosimilar product and due to their clinical familiarity and confidence, were leaders in its early adoption, helping to drive patient access to this high quality, lower cost treatment across both platforms. 1 Oncology and RCA physicians are leading in the adoption of advanced and individualized treatment approaches, expanding access to its clinical trials and ensuring patients have access to the most cutting edge treatments in an accessible setting.

In closing, Suncor delivered a strong start to our fiscal 2026 and continues to execute at a high level. We’re advancing our strategy and strengthening our position as a leading healthcare company. Guided by our purpose, growth priorities and strategic drivers, we are well positioned to drive sustainable value creation for our stakeholders over the long term. Before handing it over to Jim for a detailed review of our quarterly results and updated guidance, I want to once again thank the Sencora team. Their expertise, commitment and dedication to our purpose power our strong performance. With that, I’ll now hand the call over to Jim for an in depth review of our performance and updated expectations for the year.

James Cleary — Executive Vice President & CFO

Jim thanks Bob. Good morning and good afternoon everyone. Before turning to a review of our fiscal 2026 first quarter financial results and updated guidance expectations, I want to take a moment to echo Bob in expressing my excitement on our announcement that we have completed our acquisition of One Oncology. One Oncology and its partner practices are leaders in community oncology. Having built a differentiated MSO platform that has delivered exceptional growth since its founding and has been a key contributor to Sencora’s leadership and specialty. As innovation and biosimilars continue to advance, our partnerships with pharmaceutical centric MSOs will allow us to better support physicians, patients and manufacturers enhancing our specialty offerings.

We are confident our investments in MSOs will unlock new value creation opportunities and support our long term growth as evidenced by our recently increased long term guidance Moving now to our consolidated first quarter results and as a reminder, unless otherwise stated, my remarks today will focus on our adjusted non GAAP financial results. For further discussion of our GAAP results, please refer to our earnings press release and presentation. Starting with adjusted diluted earnings per share, we completed the quarter with adjusted diluted EPS of $4.08, an increase of 9% driven by performance in our US Healthcare Solutions segment.

Consolidated revenue was $85.9 billion up 5.5% due to solid growth in both reportable segments and in other the drivers of which I will detail when I speak to our segment level results. In the quarter, we continued to see strong sales growth in the US for GLP1 products which increased by $1 billion or 11% over the prior year quarter. Turning to gross profit, Consolidated Gross profit was $3.0 billion, up 18% primarily due to growth in the U.S. health Care Solutions segment. Consolidated gross profit margin was 3.48%, an increase of 37 basis points driven by the January 2025 acquisition of retina Consultants of America.

Moving to operating expenses in the quarter, consolidated operating expenses were $1.9 billion, up approximately 22% driven primarily by the RCA acquisition and to support our revenue growth. Consolidated operating income was $1.1 billion, an increase of 12% compared to the prior year quarter due to strong execution by our teams and continued growth in our U.S. healthcare Solutions segment. Moving now to our net interest expense and effective tax rate for the first quarter, net interest expense was $72 million, an increase of $44 million versus the PR primarily due to debt raised to finance a portion of the RCA acquisition.

Our effective income tax rate was 19% compared to 20% in the prior year quarter and as we look at the balance of fiscal year 2026, we now expect our full year effective tax rate to be approximately 20%. Finally, diluted share count was 195.3 million shares, a 0.1% increase compared to the prior year first quarter. As a reminder, due to the One Oncology acquisition, we have paused share repurchases as we prioritize debt paydown and anticipate our full year diluted share count to be approximately 195.5 million shares. Regarding our cash balance and adjusted free cash flow, we ended December with $1.8 billion of cash and had negative adjusted free cash flow in the quarter of $2.4 billion as a result of seasonal working capital needs.

This compares to negative adjusted free cash flow of $2.8 billion in the first quarter of fiscal 2025. We continue to expect full year adjusted free cash flow to be approximately $3 billion as the working capital dynamics unwind in the balance of our fiscal year 2026 as they did in fiscal year 2025. This completes the review of our consolidated results. Now I’ll turn to our segment results for the first quarter beginning with the U.S. healthcare Solutions segment. U.S. healthcare Solutions revenue was $76.2 billion, up 5% as we continue to see good volumes and revenue growth across our customer segments, including growth in GLP1s and in specialty sales to health systems and physicians.

As a reminder this quarter we faced a more challenging revenue comparison due to a large grocery customer we off boarded in the second quarter of fiscal 2025 and the fourth quarter. Fiscal 2025 loss of an oncology customer as a result of it being acquired, US healthcare solutions segment operating income increased 21% to $831 million, primarily driven by the RCA acquisition and continued specialty growth in health systems and physician practices. More than offsetting the headwind from the oncology customer loss, our teams continue executing at a high level across the segment, contributing to our strong performance. In the quarter, we saw particularly good volumes and trends in our health systems business where we continue to see benefits from our focus on strategic partnerships, leveraging our expertise and specialty.

At rca, we saw better than expected volume, excellent trends in research and new physicians joining the platform. Turning now to our international Healthcare Solutions segment. In the quarter, International Healthcare Solutions revenue was $7.6 billion, up approximately 10% on an as reported basis and 6% on a constant currency basis, driven primarily by our European distribution business, but also reflecting revenue growth at each of the businesses within the segment. International Healthcare Solutions operating income was $142 million, down 14% on an as reported basis and down 17% on a constant currency basis. The decline was driven by lower operating income in our European distribution business, largely due to the timing of manufacturer price adjustments in a developing market country, partially offset by operating income growth in our global specialty logistics business.

In the quarter we continued to see encouraging trends for our global specialty logistics services. With volumes growing again this quarter, our teams have been prioritizing operational excellence and targeted business development which are positioning us for success as the market begins to rebound. Moving to other revenue in other was $2.1 billion, up 6% primarily due to growth at MWI Animal Health and Profarma and offset in part by a revenue decline in our legacy US hub consulting services. Operating income was $91 million, down 6% primarily due to a decline in operating income in our US hub consulting services business resulting from the fiscal 2025 loss of manufacture program, partially offset by operating income growth at MWI Animal Health where the teams continue to execute well across companion and production animal markets.

That completes a review of our segment level results. I will now discuss Our updated fiscal 2026 guidance expectations. As a reminder, we do not provide forward looking guidance for certain metrics on a GAAP basis, so the following information is provided on an adjusted non GAAP basis except with respect to revenue beginning with adjusted diluted earnings per share. When we announced the acquisition of One Oncology, we indicated that we had expected to be towards the lower half of our EPS range due to pausing of share repurchases. Today we are pleased to now be reaffirming our full guidance range of $17.45 to $17.75 to reflect our strong execution, the continued performance of our U.S.

healthcare Solutions segment and the expected contribution from One Oncology. Moving now to revenue, we expect consolidated revenue growth to be in the range of 7 to 9% up from the previous expectations of 5 to 7%, reflecting increased growth across both reportable segments and in other. In the US Healthcare Solutions segment, our guidance reflects 7 to 9% revenue growth which includes the One Oncology MSO revenue and continued solid utilization trends across the segment. In the International Healthcare Solutions segment, we now expect revenue growth to be in the range of 7 to 9% on an as reported basis to reflect the weakening of the US Dollar against many currencies on a constant currency basis, our International Healthcare Solutions segment revenue growth growth remains unchanged at 6 to 8% growth.

For other we now expect revenue growth to be in the range of 1 to 5% reflecting updated expectations for profarma and positive volume trends we have seen at MWI which represents a significant majority of revenue and other. Moving to operating income, we expect consolidated operating income growth to be in the range of 11.5 to 13.5% up from the previous guidance of 8 to 10%. This is primarily driven by our increased growth expectations for the US Healthcare Solutions segment where we now expect operating income growth to be in the range of 14 to 16% due to our acquisition of one oncology and the continued strong execution and performance of the segment.

As a reminder, we expect One Oncology to be neutral net of financing costs to adjusted diluted eps in its first 12 months. There is no change in our full year operating income expectations for the International Healthcare Solutions segment as the largest driver of the year over year weakness for the first quarter was timing related within the European distribution business which we expect to pick up in the balance of fiscal 2026 as it relates to our operating income expectations. For other we now expect to see operating income flat to the prior year Revised Reportable Segment Results this is due to the full impairment of depreciable assets of the U.S.

consulting business as of December 31, 2025, thereby eliminating the need for future depreciation expense. While this consulting business is small in the context of the Sencora enterprise, we are pleased that we are making progress on focusing our portfolio before moving to our updated interest expense expectations. I wanted to spend a moment providing details on non operating income contributions we expect from the One Oncology acquisition. Due to the nature of non wholly owned investments held by One Oncology, we expect to have the following two additional benefits to Sencor’s net income. First, we expect to record approximately $30 million of income on our other income and loss line for the full year fiscal 2026, primarily relating to a joint venture in which one Oncology’s UUG subsidiary holds a non controlling stake.

Second, we expect to have a non controlling loss add back to net income also related to UUG that will largely offset the non controlling income we eliminate from Pro Pharma resulting in our non controlling interest line being relatively small in fiscal 2026. While these items are helpful call outs as you incorporate One Oncology into your models for Sencora, we do not anticipate them being regular points of discussion. The One Oncology platform is well positioned, high performing and will be a meaningful contributor to Sencora’s operating income both in 2026 and in our long term plans. Moving now to interest expense, we expect interest expense to be in the range of $480 million to $500 million, up from our previous range of $315 million to $335 million primarily due to additional borrowings required to fund our acquisition of One Oncology.

As a reminder, our second quarter is typically our highest interest expense quarter due to the seasonal working capital needs and with the One Oncology financing, we would expect second quarter net interest expense to be about double our first quarter interest expense that concludes our updated full year guidance assumptions. In closing, Sancora delivered a strong start to fiscal 2026 as our purpose driven team members executed to support our partners and patients. Our strategy, centered on our growth priorities and strategic drivers, is powering our performance, informing our capital deployment and will allow us to drive long term value creation for all our stakeholders.

Now I’ll turn the call over to the operator to open the line for questions. Operator.

Questions and Answers:

operator

Thank you. To ask a question, please press STAR followed by one on your telephone keypad. Now if you change your mind, please press STAR followed by two. When preparing to ask your question, please ensure your device is unmuted locally. The first question comes from Glenn Santangello from Barclays. Your line is now open. Please go ahead.

Glen Santangelo

Yeah, thanks for taking my question. Hey Bob and Jim, I’m just going to talk about operating income growth for a second for the balance of the year. I think with so many moving parts like around, you know, rc, the Retina deal and Florida Cancer and now adding one oncology, I think what the market’s kind of confused a little bit about is the deceleration, Jim, that we saw in that in the US Segment from the September to the December quarter. And so I’m kind of curious if you can give us a little bit more color there and within your full year guidance, should we just assume continued deceleration throughout the year due to the more difficult comps and I don’t know if there’s any other headwinds or tailwinds to that operating income line that you think are worth calling out as we think about the balance of the year.

Thanks.

James Cleary

Sure, sure, Glenn, Thanks a lot for asking that question. And you know, I’ll start out with the December quarter and during the December quarter, as you know, in the US we had adjusted operating income growth of 21%. And I’ll start out talking about our long term guidance. As you know, our long term guidance for adjusted operating income growth in the US is 7 to 10%. And we’ve increased that twice in the last few months. And the reason I bring that up, if you look at the first quarter and look at that 21% operating income growth in the U.S.

if you back out RCA and RCA had a very good quarter. But if you back out rca, our performance in the US was still towards the higher end of our long term guidance range. And that’s even with the headwind from the oncology customer that we lost. And so if you back out that headwind, we were meaningfully above our long term guidance range. In the first quarter in the US and really those positive results are due to things like utilization trends. We’ve talked about for some time, really strong performance in specialty in the quarter. We had particularly good performance with health systems, but also with physician practices and really good sales to, to both one oncology and RCA and then just broad performance across the U.S.

segment. And so as a result of that, and as a result of the contribution of course from One Oncology, we’re increasing our guidance for the full year from in the US from 9 to 11% adjusted operating income growth to 14 to 16%. And so if we look at the balance of the year guide that you asked about and if we exclude RCA and exclude 1 oncology, we’re still solidly within that long term guidance range of 7 to 10%. And that’s in spite of the headwind that we have from the loss of the oncology customer that was acquired by a competitor.

And again, that, you know, very good performance is, you know, is driven by the same factors and including utilization trends, strength in specialty sales and broad based performance. And so if you look at our performance now, I think we are performing really well. It may not be the same level of outperformance that we’ve had in some of the recent past. Of course, the comps that we’re hitting are very strong comps. But I will say that we feel very good about our long term guidance and very good about even when you X out things like RCA and One Oncology where performing, you know, solidly within that long term guidance range that we’ve increased a couple times in the last few months.

So thanks a lot for the question. Glenn.

operator

Thank you. The next question comes from Elizabeth Anderson of Evercore isi. Your line is now open. Please go ahead.

Elizabeth Anderson

Hi guys, good morning and thanks for the question. Appreciate all the details. I was wondering if you could go into a little bit more detail on some of the MSO platform AOI accelerators such as, you know, you’ve owned RCA for about a year, you obviously have. Just rolled up One Oncology, you know. In terms of closing that where are the like shorter term opportunities in terms of helping to drive AOI growth and what’s sort of like a longer term, you know, driver as we think about. That platform going forward. Thank you.

Robert Mauch

Hi Elizabeth, thank you for the question. You know, I’ll just, I’ll take a step back and just kind of, you know, revisit, explain a bit, kind of why the MSOs fit so well within the Syncore strategy and I’ll get right to your specific question. But the MSO strategy is a natural extension of the relationship that we have with specialty providers as well as specialty biopharma. It’s in addition to the strong businesses that we have, especially distribution and gpo. So the acquisition of RCA was a good, important first step. And as we saw the performance of that business, it became clear to us that we should, if we could accelerate the acquisition of one oncology, which we’re extremely happy that we were able to accomplish.

So what that gives us now, which gets to your question is now we have two platform MSOs who are market leaders with significant capabilities within each MSO. And then the answer to your question is as we look across those MSOs, we have opportunities to leverage those capabilities, which we’ve talked about and we restated in the prepared remarks today. But the clinical trial excellence that exists within RCA is something that we believe we can quickly leverage across the entire platform. Revenue cycle management is a very strong capability within the MSOs that can become even stronger. That’s a value driver.

And then things, you know, around, you know, future products and future technologies that these excellent physicians have leadership in, that’s where you get to a little bit of the medium and the longer term. We’re confident that there will be new capabilities and new services that will be built over time that most importantly will be there to support the physicians and, you know, to restate again, the purpose of the MSO is to support the physicians and the physician practice that allows them more time to focus on their patients, on clinical excellence and driving. So as we build those capabilities, we have the scale and the footprint now to deploy them in a significant way.

So we have short term opportunities, which we talked about, but we’re also excited about medium and long term opportunities that we’ll talk more about once they become more apparent.

operator

Thank you. The next question is from Lisa Gill of JP Morgan. Your line is now open. Please go ahead.

Lisa Gill

Thanks very much, Bob. I have one question for you and then just a follow up for Jim. Bob, on your side, I appreciate everything you’re talking about from an MSO perspective and the physician relationship, but one of the comments that stood out to me today is the benefits of strategic partnerships with health systems. Can you talk a little bit more about the opportunities that you see there? You know, what’s in the numbers today and what the future opportunity is.

And then, Jim, can you just help us to understand the cadence of earnings? I just want to make sure. I know you don’t give quarterly guidance, but anything to call out as we think about the next several quarters.

Robert Mauch

Hi Lisa. Yeah, thank you for the question. We certainly are focused on the MSOs today, but your question is spot on with our strategy and the way that we think about our specialty business because certainly the community physician side of care is critically important for patients and for Syncora. But, but we also see significant growth in our relationship with health systems who are also focused on that specialty growth. And we’ve been focused there over a number of years. We feel really comfortable with the customer portfolio that we have and we expect to continue to see growth there.

And as I mentioned in my prepared remarks, we spend a lot of time understanding those customers, these health systems customers, understanding their strategy, how they want to grow. And then we bring the capabilities of Syncor to help them do that. And so that’s, that’s worked out well to this point. We expect it will continue. But your question really is indicative of the way that we think about the specialty pharmaceutical growth and that we want to be a leader in the sites of care where all of our customers are. And we’re doing that. So certainly in the physician space, the health systems, but then others as well, we want to make sure that we’re the right partner for those providers.

James Cleary

Thanks for the question, Lisa. Thanks a lot. For the follow up question. I’ll just call out two things. The first is of course, the oncology customer that was acquired by a competitor that will be a headwind like it was the last two quarters. That’ll be a headwind in the second and third fiscal quarter. And then we’ll no longer have that headwind in the fourth quarter which will enhance our operating income growth rate in the fourth quarter. And then the only other thing I’ll call out, which I said in my prepared remarks, we kind of gave a lot of detail here to help with the modeling, is due to the debt that we’re taking on to fund and the one oncology acquisition, we’re indicating that our interest expense in the second quarter will be approximately two times our interest expense in the first quarter.

Thanks a lot for that follow up question.

operator

Thank you. The next question comes from Michael Cherney of Learinc Partners. Your line is now open. Please go ahead.

Michael Cherny

Good morning. Thanks for taking the question. Maybe if we can talk about the market construct a little bit. Obviously the first range of IRA price negotiations hit the market start this year. Can you just give a sense as you prepared for calendar 26, any changes or discussions relative to the supplier side in terms of how you go to market and any changes in terms of the contracting relative to any of the list price changes that were absorbed.

James Cleary

Yeah, let me make a couple comments there. Thank you for that question. You know, we have, you know, very strong strategic global sourcing team and we were well prepared. And when there were the reductions in list price, as we’ve said before, we have, you know, terms in our contracts which indicate that we’ll get into discussions with manufacturers. And we were, you know, very successful in those discussions with manufacturers because of the value we provide in the supply chain. So we were very successful in maintaining our economics and our gross profit dollars. And so we were pleased with the way that that turned out.

And we had talked about for some time the insulin example and how we have protected our gross profit dollars. And this was just another example at the end of this year of us because of the value we provide in the supply chain, able to come out of those discussions with maintaining good economics and gross profit dollars. And then the only other thing I’ll comment on is just in general, what we saw at the end of the year in terms of, you know, brands and any price increases and those sorts of things was very much in line with our expectations.

Thank you very much for the questions.

operator

Thank you. The next question is from Erin Wright of Morgan Stanley. Your line is now open. Please go ahead.

Erin Wilson Wright

Great, thanks. So I’ll switch to international. It does seem to be more of a timing dynamic. Can you describe that a little bit more? Is there a specific geography that this was attributable to in terms of in the quarter and I guess give a little bit more detail on what that headwind was or quantify it for us and then what gives you confidence in that ramp? What are you seeing in like Courier, for instance, in other areas as well? Thanks.

James Cleary

Yeah, thank you. Appreciate the question, Erin. And so I think the key thing is that in the international segment we’re maintaining our operating income guidance, adjusted operating income growth of 5 to 8% for the fiscal year. And what we saw during the first quarter in the international segment was a challenging quarter due to a timing difference for manufacturer price adjustments in a developing market country. And that price adjustment last year happened at the beginning of the fiscal first quarter and this year it happened at the very end of the fiscal first quarter. And so that’ll really just be a timing difference that we’ll see year over year.

And as a result of that, there’s no change in our guidance for the fiscal year and we expect it to pick up in the balance of the fiscal year. But then I think in the international segment. The thing we were really pleased to see during the quarter is operating income growth in our global specialty logistics business. And what we’ve seen the last two quarters is really volume growth in that business. And so we’re executing well as a team there. And we’re really pleased by the positive signals that we’ve seen of volume growth there. And of course that translated in the most recent quarter to operating income growth.

So those are the things that enable us to maintain our guidance of 5 to 8% in international for the fiscal year. Thank you, Erin.

operator

Thank you. The next question comes from Stephen Baxter of Wells Fargo. Your line is now open. Please go ahead.

Stephen Baxter

Hi, thanks. Also going to spend a minute on the revised U.S. it looks like that came up about 160 or $170 million. I was hoping you could perhaps break that into perhaps the contribution from One Oncology. Whether we should think about any kind of transitory costs or kind of ramping going on with that business to kind of consider. And then in terms of organic guidance provision, is there any organic guidance provision in the segment? A lot to point to there. Thank you.

James Cleary

Yeah, thanks a lot for the question. And of course in the U.S. we increased our guidance from 9 to 11%, as you know, to 14 to 16%. And that was driven by the One Oncology acquisition and also by continued performance in our U.S. healthcare Solutions segment for all the reasons that we’ve been talking about. And as I said before, if you back out RCA and you back out One Oncology in the first quarter, we’re towards the higher end of our long term guidance range of 7 to 10%. And in the last three quarters if you back out RCA and one oncology, again where we’re within that long term guidance range and both those things are in spite of the loss of the oncology customer that was acquired.

Now one other thing that I want to raise, and this is why we got into a little bit of detail in my prepared remarks, is there are some one Oncology benefits that happen below the operating income line and part of those benefits are in the other income line and part of those benefits are in the non controlling interest line. And these were covered. But just to quickly go through them, we expect approximately $30 million of income in our other income and loss line for the full year fiscal 2026. And that’s primarily related to earnings from a joint venture in which UUG holds a non controlling stake.

And then second we expect to have a non controlling loss add back to net income also related to UG and just the size of that. This add backs will largely offset the non controlling income we eliminate from Pro Pharma and that results in our non controlling interest line being relatively small in fiscal 2026. And that’s a lot of detail there. But we just really wanted to make the point that there’s the operating income benefit from one Oncology and then there’s also some income below the operating income line.

operator

Thank you. The next question comes from Eric Percher of Nephron Research. Your line is now open. Please go ahead.

Eric Percher

Thank you. Jim, I might ask you for a little bit more detail on top of that detailed description. When you look at the US healthcare op profit increase, the 9 to 11 to 14 to 16%, it looks like this quarter’s performance would add a point recognizing there’s a range here. But can you remind us maybe how the one Onco acquisition contribution flows in at the segment level versus what you gave us at total company being neutral and how much of that is attributed February 2nd to the end of the fiscal year?

James Cleary

Yeah, thanks for asking that follow up question. And so the increase in guidance from 9 to 11 to 14 to 16% in the US is largely driven by one oncology and it’s also as a result of the continued strong performance in the US and you know what you’ll see is in the other income line for the first four months of the fiscal year we have our, you know, our 35% of the net after tax earnings from one oncology and that’s after interest after tax. So it’s a relatively small number. And then of course that moves up to operating income for the last eight months.

And so it’s really just kind of eight months there that drives the increase from 9 to 11% to 14 to 16%. And you know just, just one other thing that I’ll add is that it does ramp. And so we’ll see the one Oncology contribution ramp as the year goes on, which is due to, you know, both organic growth and inorganic growth. Some, some inorganic growth that we’ll see there. But we do see a nice ramp over the course of, of the fiscal year that will of course continue to ramp in future years. Thanks a lot, Eric.

operator

Thank you. The next question is from Alan Lutz of Bank of America. Your line is now open. Please go ahead.

Allen Lutz

Good morning and thanks for taking the questions. One for Jim. You mentioned if you back out RCA1 oncology, you’re toward the high end of the long term EBIT guidance in the. Quarter and then over the last three. Quarters here within that range, how should we think about what’s embedded in that core business for the rest of fiscal 26 if we exclude RCA and one oncology, should we just assume it’s basically within that? And then what gets you within US Healthcare solutions on the EBIT side? What gets you to the low end. And the high end of that range? Thanks.

James Cleary

Yeah. And you know, really it’s the things we’ve been talking about for quite some time. And so it’s solid utilization trends, it’s strength and sales of specialty to both health systems and physician practices. And we’ve seen really strong performance there in health systems given our strength and specialty in oncology that’s really helped us with health systems and then broad based performance throughout our U.S. business. And so it’s really, you know, just kind of all those sorts of things and it’s a range because of course it’s very strong performance and it’s just kind of what’s that level of strong performance within the range? And then of course, you know, our business has been good for, you know, for so long that we have, we have strong comps that we’re comparing against.

But also we have a lot of confidence in our guidance because of our success and because of those underlying trends that we’ve been talking about for quite some time. Thanks a lot for the question.

operator

Thank you. The next question is from Charles Re of TD Cohen. Your line is now open. Please go ahead.

Charles Rhyee

Yeah, thanks for taking question, Jim. Maybe just to go back to the below the line items related to one on call. I guess if I remember correctly, when you announced the deal, you know, you guys did say that you wouldn’t be consolidating 100% of that. And I assume that this is that portion that is not being consolidated and will continue to be below the line. You know, you call it out this time. But is it right to think that this 30 million amount is an ongoing kind of NCI piece that we should be modeling? And then, and I guess then, you know, we think, you know, how much of that.

So I guess really how much of total oncology are you owning in going to the future? Is this like, you know, is this like a 10% piece that will remain kind of staying outside or is it less? And then, and then if I could just add a follow up on share repurchase, I understand you’re pausing in the short term, but when I look at your total leverage, it’s still pretty low and would seem like you would have ability to do both, both pay down debt and buy shares Would love to understand maybe you’re thinking why you necessarily have to pause if there’s any kind of covenants or anything like that.

Thanks.

James Cleary

Okay, great. There was a lot there in that question. And what I’ll say is that the two below the line items that I referred to, they’re specifically related to One Oncology’s UUG subsidiaries and they will continue to be there over time and will continue to have those benefits that below the line, below the operating income line contributions as a result of that. The second part of the question had to do with our ownership stake in One Oncology. And we increased our ownership stake when we made the announcement today from 35% to 92%. And we’re really pleased to say that the practices and management will own the remaining 8%.

And so I think that was the second part of the question. And then the third part of the question was share repo. And as we’ve said, you know, we’re pausing share repo and focusing on deleveraging. But I will add that our long term capital deployment priorities remain the same, which are of course, investing in the business, strategic acquisitions that you’ve seen, share repurchases that you’ve seen over time and then, you know, having a nice growing dividend which we grew at 9% this year. So thanks a lot for the question.

operator

Thank you. The next question is from George Hill of Deutsche Bank. Your line is now open. Please go ahead.

George Hill

Good morning guys and thanks for taking the question. And Jim, I’m going to ask another one on MSO accounting. So first I guess my question is could you unpack a little bit of the revenue guidance change in the US business, about $5.7 billion. And I’m interested if you can provide some color on the One Oncology contribution, the growth in the core and kind of how to think about any of the puts and takes in WAC price reductions, whether or not that played a point at all, I recognize that you guys have offset it at the earnings line.

I’m surprised. There’s kind of no impact on the revenue line at all and maybe growth of GLP1s. And then my quick follow up would be, I know that we were all looking at the One Oncology acquisition as a multiple of ebitda. Is that EBITDA number the right proxy to use for AOI as we model One Oncology? Are there any significant puts and takes between the AOI line and the EBITDA line for One Oncology? Thank you.

James Cleary

Yeah, so there was a couple things there in that question. The first was on revenue and revenue guidance. And you know, one oncology does not have a large impact on our, on our revenue guidance and the growth there. And of course the MSO business model is a lower revenue business model but a really nice operating margin business model. And that’s, you know, similar to what you’ve seen from rca. It really impacts our, our operating income margin. And then the other thing I’ll say there is, you know, we don’t count the revenue twice that we, you know, of course we sell to MSO but only count the revenue once, of course, and I’m sure you’re aware of that.

And then the other things I’ll say is that as we look at our revenue growth this year, of course, and we have a grocery customer that we off boarded and we also have the oncology customer that was acquired by a competitor so that impacts our revenue growth this year. And then also we fully anticipated the changes in list prices when we put together our revenue guidance for this year. And so we’re pleased with the increase in guidance because it just shows, you know, the underlying strength of our business when we have the increase in revenue guidance.

And then, you know, you asked a question about, you know, kind of any differences between EBITDA and operating income other than the components. There is no meaningful difference there that I would, you know, call out other than of course the depreciation and amortization. Thanks, thank you for the questions.

operator

Thank you. The next question is from Stephen Velikat of Mizuho. Your line is now open. Please go ahead.

Steven Valiquette

Yeah, great. Thanks. Good morning. So I guess within the international business your revenue growth is pretty strong. Any color? Just on the drug pricing trends in Europe. Really on the back of all the MFN drug related policies from the US might be impacting pricing into Europe or uk. Any impact for that one way or the other? Or is it just kind of business as usual in Europe aside from your one call out in that developing country? Thanks. Hi Steve, thanks for the question. I’m going to take this so we can give Jim a break and he can take a sip of water here.

But no, we haven’t seen any real changes in the markets from mfn. So as, as Jim said earlier and you just restated, we did have the timing issue in one market. Overall the international business is performing within our expectations and we expect to meet our fiscal 26 commitments there. But no changes based on MFN. We’re also seeing Steve, which maybe a sub bullet of your question kind of within. We talked about the world Courier business improvement. But you know, I do want to state how strong our growth is in our global 3PL platform. So again part of our specialty strategy and within that specialty strategy in Europe, those products are delivered, you know, through three pl, not necessarily through wholesale and we have a pan European market leading service there that also includes obviously the United States and all of North America.

So which is, which is performing very well but full circle. No real changes in pricing that we’re seeing in that market. Thanks for the question.

operator

Thank you. The next question comes from Kevin Caliendo of ubs. Your line is now open. Please go ahead.

Kevin Caliendo

Hi. Thanks for taking my question. I want to change it up a little bit. There was a, a relatively credible story about a private equity firm potentially being interested in buying nwi. I don’t want you to, I know you’re not going to comment on the story, but just broadly speaking, can you talk about how you think about asset divestitures in the context of long term growth rate or impact to long term growth rates impact near term to earnings like does that, would you contemplate dilution or anything like that if strategically it made sense for you long term and also maybe just speak to what’s happening in that marketplace right now in MWI’s positioning.

You called it out, had a good quarter. I’m just wondering strategically how it fits long term for you guys.

Robert Mauch

Yeah, thank you for the question. As you said, we’re certainly not going to comment on any rumors but I will reiterate, you know what we said very specifically last quarter and really have been working on over the past year or so and that is our strategy is being refocused and one of our strategic drivers is to make sure that we’re prioritizing growth oriented investments. And so we went through a process of assessing all of our businesses to make sure that they are very well aligned with our strategy and our future strategy going forward and made the determination that we would put certain businesses in the other other category.

And at that time we said we would be looking at strategic alternatives for, for those businesses in other. The purpose of that is really to create that focus, management focus and strategic focus. And then we believe growth rate benefit from doing that. But I’ll hand it over to Jim and talk about some of the potential short term impacts if any divestitures were to occur.

James Cleary

Let me comment on a couple of things that you said. First of all, MWI continues to perform very well within its market. In this most recent quarter it had 7% revenue growth and perform well in both the companion and production animal market. So we’re pleased that it continues to perform well. With regard to one aspect to your question is any potential dilution from a divestiture? You know, from some divestitures there could be potential dilution, but as Bob was saying, you know, we think it’s the right thing to do for the long term. And one of Bob’s real strategic priorities is to to prioritize growth oriented investments, as he was saying.

And that’s why we’re investing in businesses like MSOs that bring competitive advantage to the balance of the enterprise. And so while there might be dilution in the short term, we think it will, you know, it could enhance growth and enhance returns over the long term. Thanks for the questions.

operator

Thank you. The next question is from Daniel Grosslight of Citi. Your line is now open. Please go ahead.

Daniel Grosslight

Thanks for taking the question. It sounds like RCA is performing better than initial expectations, which has been the case for the past couple quarters here. Now I think when you initially announced that deal, you were thinking around 50 cents of accretion from RCA in the first full year. There was that kind of accounting change. So accounting for that, now that we’ve passed that one year, Mark, I was wondering if you could provide an update on how much accretion you saw from RCA in the first year or maybe quantify that outperformance for us and then maybe provide a little bit more detail on the sources of that outperformance.

Thanks.

James Cleary

Sure. Yeah. Yeah. We’ve continued to see very strong performance at RCA and we’ve seen, you know, good performance organically and we’ve seen good tuck in acquisition opportunities. So we’ve been just, you know, really pleased by the performance of the team there. And we’ve, you know, exceeded the expectations that we had in the clinical trial part of the business, but really performed well throughout the business. So we’re very pleased with the acquisition and seeing the growth continue to ramp over the balance of the year. And then, hey, just one follow up. I want to make on the One Oncology some of the below the operating income line items that I was referring to.

I just want to make it clear that, you know, those are accounting nuanced items related to one of the One Oncology subsidiaries, related to the UUG subsidiaries. And this will be a part of the model going forward. It’s not one time. So we’ll continue to have that benefit from One Oncology below the operating income line. But we don’t anticipate that we’ll be talking much about it, you know this year or in the future years because you know we fully expect given the strength of the very strong performance we’ve seen of the business in the past and what we expect that they’ll be very good operating income growth.

And thank you for the RCA question also.

operator

Thank you. That concludes today’s Q and A session. So I’d like to hand back to Bob for closing remarks.

Robert Mauch

Thank you very much. In all seriousness, I do want to thank Jim for carrying the heavy load today and thank you all for your questions and interest today. I’m proud of how CENCOR continues to execute to drive value for all our stakeholders investing internally in our infrastructure and externally to extend our solutions for customers. We’re well positioned to drive long term growth and are pleased to have raised our long term guidance this year demonstrating our confidence in our ability to continue to execute and create shareholder value. Thank you all very much.

operator

This concludes today’s call. Thank you Sam.